Navigation Links
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Date:10/23/2007

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin. These compounds could enter human clinical trials in late 2008.

"Bis-platinates represent a promising new class of platinum-based chemotherapy drugs with a potential broad spectrum of anti-tumor activity. Anti-cancer drugs containing platinum are a cornerstone therapy for a wide range of tumor types including ovarian, testicular, colorectal, head and neck, and lung cancer," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "These bis-platinates, unlike the currently approved platinum compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The preclinical studies presented at this meeting suggest these compounds are substantially more active than the existing monoplatinates -- especially against platinum-resistant tumors. These agents could represent a significant advance in the treatment of a wide variety of cancers."

Novel bisplatinum complexes characterized by an improved in vitro plasma protein binding and in vivo efficacy on xenograft models (Abstract A267)

Scientists from CTI-Europe presented data on two novel bis-platinum complexes, CT-47613 and CT-47609. When tested in animal models of ovarian cancer and colon cancer, the bis-platinates were significantly more potent than the two most commonly used platinum based chemotherapy drugs, carboplatin and cisplatin and oxaliplatin. Importantly these agents demonstrated potent anti-tumor activity in tumors with either acquired or intrinsic resistance to cisplatin or carboplatin, representing the first such class of binuclear platinum based
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 /CNW/ - CQDM, Brain Canada and ... to six (6) multi-disciplinary and multi-provincial research teams across ... Focus on Brain strategic initiative. To this amount, $1.5M ... in-kind contributions. This exciting announcement was made today at ... in the presence of Inez Jabalpurwala, President and CEO ...
(Date:5/27/2015)... 2015 The ALS Therapy Development ... wholly owned subsidiary, Anelixis Therapeutics , $1.5 million ... that targets the innate immune system. The funding comes ... received from the 2014 social media phenomenon known as ... $4 million raised directly by the Institute through last ...
(Date:5/27/2015)... , May 27, 2015  CytomX, a biotechnology ... cancer, today announced the appointments of Bob ... Cynthia Ladd as senior vice president and ... chief financial officer of Onyx Pharmaceuticals, an Amgen ... consultant and legal counsel to several leading biotech ...
(Date:5/27/2015)...  Two years after its founding by a community ... Oakland -based Counter Culture Labs (CCL) ... to democratize science through a full-fledged community laboratory space ... Photo - http://photos.prnewswire.com/prnh/20150526/218366LOGO ... Based out of the new Omni Commons , ...
Breaking Biology Technology:Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3
... New Rochelle, NY, February 8, 2011Successful intranasal delivery ... with Parkinson disease yielded significant improvement in motor ... the disease. These highly promising findings, reported in ... by Mary Ann Liebert, Inc. highlight the potential ...
... Feb. 16, 2011 Pneumococcus ( Streptococcus pneumoniae ... of mortality in young children worldwide. While successful ... only work against specific pneumococcal strains, with the ... emerge. Through a novel discovery approach, researchers at ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... of its common stock, including 900,000 shares sold pursuant ... granted to the underwriters. The shares were sold at ... in aggregate gross proceeds to Optimer of $77.6 million, ...
Cached Biology Technology:New Pneumococcal Vaccine Approach Successful in Early Tests 2New Pneumococcal Vaccine Approach Successful in Early Tests 3New Pneumococcal Vaccine Approach Successful in Early Tests 4Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock 3
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2
... Seawater is a complex, dynamic mixture of dissolved ... best efforts, presents difficulties in measuring its potential ... itself, the calculations scientists employ to measure seawater ... the years as research techniques and instrumentation continues ...
... Baltimore, MDDouglas E. Koshland, staff scientist at Carnegie,s ... 72 Fellows by the American Academy of Microbiology. ... peer-review process, based on their records of scientific ... , Using the simple, single-celled yeast Saccharomyces ...
... Researchers have found evidence that a direct interaction between ... risk of developing multiple sclerosis (MS). The research, published ... Genetics , suggests that vitamin D deficiency during pregnancy ... the offspring developing MS later in life. MS ...
Cached Biology News:New equation of state of seawater 2New equation of state of seawater 3Carnegie's Doug Koshland elected Fellow of the American Academy of Microbiology 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
prototype Nco I...
Request Info...
Biology Products: